Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis

Bibliographic Details
Main Author: Martins, Diana Mafalda Miranda
Publication Date: 2015
Other Authors: Matos, Cristiano, Joaquim, João José Morais, 1969-
Format: Article
Language: por
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10400.26/15532
Summary: Multiple Sclerosis (MS) is a chronic, autoimmune, neurodegenerative and demyelinating disease of the central nervous system, which affects the quality of life of patients and their families. This disease is characterized by relapses or exacerbations, which are clinical consequences of increased inflammatory activity in the CNS. Few treatment options for patients with secondary progressive multiple sclerosis (SPMS) is available. Mitoxantrone (type II topoisomerase inhibitor) could be used to treat MS, most notably the subset known as SPMS. Mitoxantrone will not cure MS, but could be effective in slowing the progression of SPMS and extending the time between relapses in relapsing-remitting MS and progressive relapsing MS.
id RCAP_4c3057df739332a57a04e1a80e71da2c
oai_identifier_str oai:comum.rcaap.pt:10400.26/15532
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosisMitoxantronaCardiotoxicidadeEsclerose múltiplaTerapêuticaFarmáciaMultiple Sclerosis (MS) is a chronic, autoimmune, neurodegenerative and demyelinating disease of the central nervous system, which affects the quality of life of patients and their families. This disease is characterized by relapses or exacerbations, which are clinical consequences of increased inflammatory activity in the CNS. Few treatment options for patients with secondary progressive multiple sclerosis (SPMS) is available. Mitoxantrone (type II topoisomerase inhibitor) could be used to treat MS, most notably the subset known as SPMS. Mitoxantrone will not cure MS, but could be effective in slowing the progression of SPMS and extending the time between relapses in relapsing-remitting MS and progressive relapsing MS.Springer InternationalRepositório ComumMartins, Diana Mafalda MirandaMatos, CristianoJoaquim, João José Morais, 1969-2016-11-21T12:09:39Z20152016-10-20T21:58:20Z2015-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.26/15532por1179-1942DOI 10.1007/s40264-015-0346-0info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-05-02T11:28:46Zoai:comum.rcaap.pt:10400.26/15532Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-29T06:48:43.753421Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis
title Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis
spellingShingle Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis
Martins, Diana Mafalda Miranda
Mitoxantrona
Cardiotoxicidade
Esclerose múltipla
Terapêutica
Farmácia
title_short Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis
title_full Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis
title_fullStr Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis
title_full_unstemmed Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis
title_sort Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis
author Martins, Diana Mafalda Miranda
author_facet Martins, Diana Mafalda Miranda
Matos, Cristiano
Joaquim, João José Morais, 1969-
author_role author
author2 Matos, Cristiano
Joaquim, João José Morais, 1969-
author2_role author
author
dc.contributor.none.fl_str_mv Repositório Comum
dc.contributor.author.fl_str_mv Martins, Diana Mafalda Miranda
Matos, Cristiano
Joaquim, João José Morais, 1969-
dc.subject.por.fl_str_mv Mitoxantrona
Cardiotoxicidade
Esclerose múltipla
Terapêutica
Farmácia
topic Mitoxantrona
Cardiotoxicidade
Esclerose múltipla
Terapêutica
Farmácia
description Multiple Sclerosis (MS) is a chronic, autoimmune, neurodegenerative and demyelinating disease of the central nervous system, which affects the quality of life of patients and their families. This disease is characterized by relapses or exacerbations, which are clinical consequences of increased inflammatory activity in the CNS. Few treatment options for patients with secondary progressive multiple sclerosis (SPMS) is available. Mitoxantrone (type II topoisomerase inhibitor) could be used to treat MS, most notably the subset known as SPMS. Mitoxantrone will not cure MS, but could be effective in slowing the progression of SPMS and extending the time between relapses in relapsing-remitting MS and progressive relapsing MS.
publishDate 2015
dc.date.none.fl_str_mv 2015
2015-01-01T00:00:00Z
2016-11-21T12:09:39Z
2016-10-20T21:58:20Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.26/15532
url http://hdl.handle.net/10400.26/15532
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv 1179-1942
DOI 10.1007/s40264-015-0346-0
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer International
publisher.none.fl_str_mv Springer International
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833602794736582656

Similar Items